levocetirizine + ambroxol (Sycon Healthcare)

SYLEV-A is a fixed-dose combination pharmaceutical product developed by Sycon Healthcare, containing the second-generation antihistamine levocetirizine and the mucolytic agent ambroxol. Levocetirizine is a potent and selective peripheral H1-receptor antagonist that reduces allergic symptoms such as sneezing, rhinorrhea, and itching by blocking the action of histamine. Ambroxol is a secretolytic agent that thins and loosens mucus (phlegm) in the respiratory tract by stimulating surfactant production and lysosomal enzyme activity, thereby facilitating mucus clearance and easing productive cough. This combination is primarily indicated for the treatment of respiratory conditions where both allergic inflammation and excessive mucus production are present, such as allergic bronchitis or productive cough associated with allergic rhinitis.

Brand names

SYLEV-A